Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial

Fernanda Mosele(Inserm), Élise Deluche(Hôpital Dupuytren), Amélie Lusque(Institut Claudius Regaud), Loïc Le Bescond(Inserm), Thomas Filleron(Institut Claudius Regaud), Yoann Pradat(Université Paris-Saclay), Agnès Ducoulombier(Centre Antoine Lacassagne), Barbara Pistilli(Institut Gustave Roussy), Thomas Bachelot(Centre Léon Bérard), F. Viret(Institut Pprime), Christelle Lévy(Centre François Baclesse), Nicolas Signolle(Centre National de la Recherche Scientifique), Alexia Alfaro(Université Paris-Saclay), Diep Thi Ngoc Tran(Inserm), Ingrid Garberis(Institut Gustave Roussy), Hugues Talbot(Université Paris-Saclay), Stergios Christodoulidis(Université Paris-Saclay), Maria Vakalopoulou(Université Paris-Saclay), Nathalie Droin(Centre National de la Recherche Scientifique), Aurelie Stourm(Centre National de la Recherche Scientifique), Maki Kobayashi(Daiichi-Sankyo (Japan)), Tomoya Kakegawa(Daiichi-Sankyo (Japan)), Ludovic Lacroix(Centre National de la Recherche Scientifique), Patrick Saulnier(Centre National de la Recherche Scientifique), Bastien Job(Centre National de la Recherche Scientifique), Marc Deloger(Centre National de la Recherche Scientifique), Marta Jimenez(UniCancer Group), Céline Mahier - Aït Oukhatar(UniCancer Group), Vianney Baris(Centre National de la Recherche Scientifique), Pierre Laplante(Centre National de la Recherche Scientifique), Patricia Kannouche(Centre National de la Recherche Scientifique), Virginie Marty(Centre National de la Recherche Scientifique), Magali Lacroix‐Triki(Institut Gustave Roussy), Véronique Dièras(Centre Eugène Marquis), Fabrice André(Inserm)
Nature Medicine
July 24, 2023
Cited by 359Open Access
Full Text

Abstract

The mechanisms of action of and resistance to trastuzumab deruxtecan (T-DXd), an anti-HER2-drug conjugate for breast cancer treatment, remain unclear. The phase 2 DAISY trial evaluated the efficacy of T-DXd in patients with HER2-overexpressing (n = 72, cohort 1), HER2-low (n = 74, cohort 2) and HER2 non-expressing (n = 40, cohort 3) metastatic breast cancer. In the full analysis set population (n = 177), the confirmed objective response rate (primary endpoint) was 70.6% (95% confidence interval (CI) 58.3-81) in cohort 1, 37.5% (95% CI 26.4-49.7) in cohort 2 and 29.7% (95% CI 15.9-47) in cohort 3. The primary endpoint was met in cohorts 1 and 2. Secondary endpoints included safety. No new safety signals were observed. During treatment, HER2-expressing tumors (n = 4) presented strong T-DXd staining. Conversely, HER2 immunohistochemistry 0 samples (n = 3) presented no or very few T-DXd staining (Pearson correlation coefficient r = 0.75, P = 0.053). Among patients with HER2 immunohistochemistry 0 metastatic breast cancer, 5 of 14 (35.7%, 95% CI 12.8-64.9) with ERBB2 expression below the median presented a confirmed objective response as compared to 3 of 10 (30%, 95% CI 6.7-65.2) with ERBB2 expression above the median. Although HER2 expression is a determinant of T-DXd efficacy, our study suggests that additional mechanisms may also be involved. (ClinicalTrials.gov identifier NCT04132960 .).


Related Papers